Harborside


Tetra Bio-Pharma Inc.

TSE: TBP


Canadian symbol: TBP.TO
US symbol: TBPMF

Currency in CAD

Valuation Measures

Market Cap (intraday) 5102.39M
Enterprise Value 393.17M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)2.87
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 7-3.47

Trading Information

Stock Price History

Beta (5Y Monthly) 2.19
52-Week Change 360.61%
S&P500 52-Week Change 334.98%
52 Week High 30.5300
52 Week Low 30.1350
50-Day Moving Average 30.2889
200-Day Moving Average 30.2899

Share Statistics

Avg Vol (3 month) 3559.95k
Avg Vol (10 day) 3437.97k
Shares Outstanding 5401.54M
Implied Shares Outstanding 6N/A
Float 365.6M
% Held by Insiders 18.63%
% Held by Institutions 15.87%
Shares Short (Aug. 30, 2021) 41.55M
Short Ratio (Aug. 30, 2021) 43.49
Short % of Float (Aug. 30, 2021) 4N/A
Short % of Shares Outstanding (Aug. 30, 2021) 40.39%
Shares Short (prior month Jul. 29, 2021) 41.41M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Nov. 29, 2020
Most Recent Quarter (mrq)May 30, 2021

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-37.82%
Return on Equity (ttm)-74.66%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -26.84M
Net Income Avi to Common (ttm)-28.36M
Diluted EPS (ttm)-0.1130
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)16.24M
Total Cash Per Share (mrq)0.04
Total Debt (mrq)3M
Total Debt/Equity (mrq)8.38
Current Ratio (mrq)3.42
Book Value Per Share (mrq)0.09

Cash Flow Statement

Operating Cash Flow (ttm)-26.15M
Levered Free Cash Flow (ttm)-15.19M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
TBP.TO
Tetra Bio-Pharma
1 month ago
TBP.TO
Tetra Bio-Pharma
1 month ago
TBP.TO
Tetra Bio-Pharma
2 months ago
TBP.TO
Tetra Bio-Pharma
2 months ago
TBP.TO
Tetra Bio-Pharma
2 months ago
TBP.TO
Tetra Bio-Pharma
3 months ago
TBP.TO
Tetra Bio-Pharma
3 months ago
TBP.TO
Tetra Bio-Pharma
4 months ago
TBP.TO
Tetra Bio-Pharma
4 months ago
TBP.TO
Tetra Bio-Pharma
4 months ago
TBP.TO
Tetra Bio-Pharma
4 months ago
TBP.TO
Tetra Bio-Pharma
4 months ago
TBP.TO
Tetra Bio-Pharma
4 months ago
TBP.TO
Tetra Bio-Pharma
4 months ago
TBP.TO
Tetra Bio-Pharma
4 months ago
TBP.TO
Tetra Bio-Pharma
5 months ago
TBP.TO
Tetra Bio-Pharma
5 months ago
TBP.TO
Tetra Bio-Pharma
5 months ago
TBP.TO
Tetra Bio-Pharma
5 months ago
TBP.TO
Tetra Bio-Pharma
6 months ago
TBP.TO
Tetra Bio-Pharma
6 months ago
TBP.TO
Tetra Bio-Pharma
6 months ago
TBP.TO
Tetra Bio-Pharma
6 months ago
TBP.TO
Tetra Bio-Pharma
7 months ago
TBP.TO
Tetra Bio-Pharma
7 months ago
TBP.TO
Tetra Bio-Pharma
8 months ago
TBP.TO
Tetra Bio-Pharma
9 months ago
TBP.TO
Tetra Bio-Pharma
10 months ago
TBP.TO
Tetra Bio-Pharma
10 months ago
TBP.TO
Tetra Bio-Pharma
10 months ago
TBP.TO
Tetra Bio-Pharma
10 months ago
TBP.TO
Tetra Bio-Pharma
11 months ago
TBP.TO
Tetra Bio-Pharma
11 months ago
TBP.TO
Tetra Bio-Pharma
11 months ago
TBP.TO
Tetra Bio-Pharma
11 months ago
TBP.TO
Tetra Bio-Pharma
11 months ago
TBP.TO
Tetra Bio-Pharma
12 months ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
1 year ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago
TBP.TO
Tetra Bio-Pharma
2 years ago

Currency in CAD
Earnings EstimateCurrent Qtr.Next Qtr.Current YearNext Year
No. of Analysts0000
Avg. Estimate0000
Low Estimate0000
High Estimate0000
Year Ago EPSN/AN/AN/AN/A
Revenue EstimateCurrent Qtr.Next Qtr.Current YearNext Year
No. of Analysts0000
Avg. EstimateN/AN/AN/AN/A
Low EstimateN/AN/AN/AN/A
High EstimateN/AN/AN/AN/A
Year Ago SalesN/AN/AN/AN/A
Sales Growth (year/est)N/AN/AN/AN/A
Earnings HistoryInvalid DateInvalid DateInvalid DateInvalid Date
EPS Est.N/AN/AN/AN/A
EPS ActualN/AN/AN/AN/A
DifferenceN/AN/AN/AN/A
Surprise %N/AN/AN/AN/A
EPS TrendCurrent Qtr.Next Qtr.Current YearNext Year
Current Estimate0000
7 Days Ago0000
30 Days Ago0000
60 Days Ago0000
90 Days Ago0000
EPS RevisionsCurrent Qtr.Next Qtr.Current YearNext Year
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesTBP.TOIndustrySector(s)S&P 500
Current Qtr.N/AN/AN/AN/A
Next Qtr.N/AN/AN/AN/A
Current YearN/AN/AN/AN/A
Next YearN/AN/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
8.63%% of Shares Held by All Insider
5.87%% of Shares Held by Institutions
6.43%% of Float Held by Institutions
6Number of Institutions Holding Shares

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
Global X Fds-The Global X Cannabis ETF11,972,226Jul. 30, 20212.98%3,112,778
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Tetra Bio-Pharma Inc.


Tetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™

Tetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™

SAA Report endorsed Tetra Bio-Pharma's proposed nonclinical development and quality programs for QIXLEEF™. SAA Report provides clarity on clinical requirements for registration in Europe. OTTAWA, ON, Sept. 2, 2021 - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived d... Read More...
Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue

Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue

OTTAWA, ON, July 29, 2021 - Tetra Bio-Pharma Inc ("Tetra" or the Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No. PCT/CA2021/050886, with a filing date of ... Read More...
Significant Discovery Reveals New Antiviral Properties of Tetra Bio-Pharma's Innovative Drug ARDS-003

Significant Discovery Reveals New Antiviral Properties of Tetra Bio-Pharma’s Innovative Drug ARDS-003

Combining ARDS-003 with antiviral drugs significantly decreased viral replication compared to antiviral treatment alone. OTTAWA, ON, June 21, 2021 - Tetra Bio-Pharma Inc. ("Tetra") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that its investigational new drug ARDS-... Read More...
Tetra Bio-Pharma Announces Clinical Advancements and Establishment of At-the-Market Equity Program

Tetra Bio-Pharma Announces Clinical Advancements and Establishment of At-the-Market Equity Program

First REBORN1© patient enters clinical trial. Positive results of first study in Sars-CoV-2 infected mice. Filing of IND for ARDS-003 Adaptive Phase 1a/1b clinical trial. /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/ OTTAWA, ON, May 28, 2021 - Tetra Bio-Pharma Inc. ("Tetra" or the "Com... Read More...
Tetra Bio-Pharma Announces $10 Million "Bought Deal" Public Offering

Tetra Bio-Pharma Announces $10 Million “Bought Deal” Public Offering

/NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, May 10, 2021 - Tetra Bio-Pharma Inc. (TSX: TBP) (OTCQB: TBPMF) (FSE:JAM1 ) ("Tetra" or the "Company") is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by Echelon Wealth Partners Inc. (the "Underwr... Read More...
Tetra Bio-Pharma Receives Second Compliant Rating on Inspection from Health Canada

Tetra Bio-Pharma Receives Second Compliant Rating on Inspection from Health Canada

Tetra Bio-Pharma Inc. receives a Notice of Compliant rated inspection to distribute pharmaceuticals Key milestone in the development path to commercialization of Reduvo OTTAWA, ON / ACCESSWIRE / April 1, 2021 / Tetra Bio-Pharma Inc. ("Tetra") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discover... Read More...
Tetra Bio-Pharma Provides Status of Its New Drug Submission Application in Canada

Tetra Bio-Pharma Provides Status of Its New Drug Submission Application in Canada

Reduvo™ would be Canada's only DIN for a THC-based prescription drug The addressable market is estimated to be $80M CDN by 2022 OTTAWA, ON / ACCESSWIRE / March 15, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announce that ... Read More...
Tetra Bio-Pharma Announces Closing of Bought Deal Offering

Tetra Bio-Pharma Announces Closing of Bought Deal Offering

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/ OTTAWA, ON, March 2, 2021 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development, is pleased to announce it has closed its previou... Read More...
Tetra Bio-Pharma To Monetize Its Dronabinol And Botanical Product Portfolios

Tetra Bio-Pharma To Monetize Its Dronabinol And Botanical Product Portfolios

Company signs LOI for Nordics and GermanyOTTAWA, ON / ACCESSWIRE / February 25, 2021 / Tetra Bio-Pharma Inc. ("Tetra") (TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announced the signing of a Letter of Intent with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Redu... Read More...
Tetra Bio-pharma Inc. Announces Upsizing of Previously Announced Offering

Tetra Bio-pharma Inc. Announces Upsizing of Previously Announced Offering

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OTTAWA, ON, Feb. 23, 2021 - Tetra Bio-Pharma Inc. ("Tetra Bio-Pharma" or the "Company") (TSX: TBP) (OTCQB: TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development, is pleased to announce today that is has entered into a revis... Read More...
Tetra Bio-Pharma Announces FDA Clearance on IND, allowing U.S. Reborn1(TM) Clinical Trial to Commence

Tetra Bio-Pharma Announces FDA Clearance on IND, allowing U.S. Reborn1(TM) Clinical Trial to Commence

OTTAWA, ON / ACCESSWIRE / January 29, 2021 / Tetra Bio-Pharma Inc. ("Tetra") (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application, allowing Tetra to initiate its QIXLEEFTM... Read More...
Tetra Bio-Pharma Inc. Announces a Non-Brokered Private Placement

Tetra Bio-Pharma Inc. Announces a Non-Brokered Private Placement

OTTAWA, ON, Jan. 27, 2021 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra Bio-Pharma" or the "Company") (TSX: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development announced today that it is conducting a non-brokered private placement of 11,141,176 units of the Company (collectively, the "Units") at a price of C... Read More...
Tetra Bio-Pharma Unveils its Commercial Vision on a Robust Chemotherapy Induced Nausea and Vomiting Portfolio

Tetra Bio-Pharma Unveils its Commercial Vision on a Robust Chemotherapy Induced Nausea and Vomiting Portfolio

DIN submission to be completed in Q4 2020 OTTAWA, ON / ACCESSWIRE / October 7, 2020 / Tetra Bio-Pharma Inc. ("Tetra") (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to provide an update on its commercial strategy to bring innovative therapies to patients suffering from chemotherapy in... Read More...
Dania Scott Joins Tetra Bio-Pharma as Senior Vice President Commercial Strategy

Dania Scott Joins Tetra Bio-Pharma as Senior Vice President Commercial Strategy

Brings over 20 years of commercial and medical expertise in the pharmaceutical industry and the cannabis spaceOTTAWA, ON / ACCESSWIRE / September 4, 2020 / Tetra Bio-Pharma Inc. ("Tetra") (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is excited to announce that Dania Scott has joined Tetra as the... Read More...
Tetra Bio-Pharma Engages Dalton Pharma for GMP Manufacturing of ARDS-003

Tetra Bio-Pharma Engages Dalton Pharma for GMP Manufacturing of ARDS-003

Significant advancement achieved with ARDS-003 sterile injectable nano-emulsion finished drug productA new anti-inflammatory drug candidateOTTAWA, ON / ACCESSWIRE / August 18, 2020 / Tetra Bio-Pharma Inc. ("Tetra") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has... Read More...
Tetra Bio-Pharma and Mondias Enter Into Final Agreement For The Purchase Of Lumiera Health Innovation Inc.

Tetra Bio-Pharma and Mondias Enter Into Final Agreement For The Purchase Of Lumiera Health Innovation Inc.

MONTREAL, QC / ACCESSWIRE / August 17, 2020 / Mondias Natural Products Inc. (TSXV:NHP) (the "Company" or "Mondias") specializing in evidence-based natural products for the healthcare and bio-agriculture markets and Tetra Bio-Pharma Inc. ("Tetra"), (TSX-V:TBP) (OTCQB:TBPMF), a biopharmaceutical leader in the discovery and development of ca... Read More...
Tetra Bio-Pharma's Management Provides Corporate Update on QIXLEEF(TM) & CAUMZ(TM) Drug Development Activities

Tetra Bio-Pharma’s Management Provides Corporate Update on QIXLEEF(TM) & CAUMZ(TM) Drug Development Activities

Resumption of its PLENITUDE© clinical trial on-time;CAUMZ™ manufacturing set to begin in USA to allow start of clinical trials;QIXLEEF™ metabolite mapping study to be complete in Q3 2020OTTAWA / ACCESSWIRE / July 28, 2020 / Tetra Bio-Pharma Inc. ("Tetra") (TSXV:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and developm... Read More...
Tetra and Mondias jointly announce the acquisition of Tetra's subsidiary, Lumiera, by Mondias to create a new growth platform

Tetra and Mondias jointly announce the acquisition of Tetra’s subsidiary, Lumiera, by Mondias to create a new growth platform

Allowing Tetra to focus on its core business of developing proprietary and scientifically validated cannabinoid-based medicines to relieve symptoms associated with advanced cancer pain, chronic pain (cancer and non-cancer pain) and ophthalmic disease. Significantly expands addressable markets, positioning Mondias to play broader role in... Read More...
Tetra Bio-Pharma's Management Provides Regulatory Update of ARDS-003 for the Potential Prevention and Treatment of Cytokine Release Syndrome

Tetra Bio-Pharma’s Management Provides Regulatory Update of ARDS-003 for the Potential Prevention and Treatment of Cytokine Release Syndrome

OTTAWA, ON / ACCESSWIRE / June 17, 2020 / Tetra Bio-Pharma Inc. ("Tetra") (TSXV:TBP)(OTCQB:TBPMF), a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery and development, today provides an update on the development of its ARDS-003 intravenous drug product for the potential treatment of cytokine release syndrome (CRS) ... Read More...
Tetra Bio-Pharma and Altus Formulation Form New Company "TALLC" to Exploit TA-A001

Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001

OTTAWA, ON / ACCESSWIRE / June 3, 2020 / Tetra Bio-Pharma Inc. ("Tetra") (TSXV:TBP)(OTCQB:TBPMF) and Altus Formulation Inc. ("Altus") today announced the launch of TALLC Corporation Inc. ("TALLC") a new Quebec company focussed on the development of TA-A001 a novel endocannabinoid CB2 receptor activator with potent anti-inflammatory analge... Read More...
Tetra Bio-Pharma Provides HCC011 Program Update Following Type B Meeting with USA FDA

Tetra Bio-Pharma Provides HCC011 Program Update Following Type B Meeting with USA FDA

HCC011 is an orphan drug designated drug-device combination product for the treatment of hepatocellular carcinoma (HCC)OTTAWA, ON / ACCESSWIRE / June 2, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has complet... Read More...
Two Quebec Companies Joined Forces to Make Healthcare Mask for our "Guardian Angels"

Two Quebec Companies Joined Forces to Make Healthcare Mask for our “Guardian Angels”

OTTAWA, ON / ACCESSWIRE / May 15, 2020 / Tetra Bio-Pharma Inc. ("Tetra") (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development and ARTOFIX a Quebec City based high performance mask manufacturer are pleased to announce that Tetra has secured a Medical Device Establishment License (MDEL) for a Class 1 medical devic... Read More...
Tetra Bio-Pharma Announces Sizing of Public Offering

Tetra Bio-Pharma Announces Sizing of Public Offering

OTTAWA, May 15, 2020 -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSXV:TBP) (OTCQB:TBPMF), is pleased to announce that, in connection with its previously announced overnight marketed offering, a syndicate of agents led by Raymond James Ltd. and Canaccord Genuity Corp. (collectively, the "Agents"), have agreed to sell 33,089,000 un... Read More...
Tetra Bio-Pharma Announces Overnight Marketed Offering

Tetra Bio-Pharma Announces Overnight Marketed Offering

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICESOTTAWA, May 14, 2020 -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSXV:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce it has commenced an overnight marketed public offering (the “Offering”) of uni... Read More...
Tetra Announces Resignation of President

Tetra Announces Resignation of President

OTTAWA, ON / ACCESSWIRE / May 13, 2020 / Tetra Bio-Pharma Inc. ("Tetra") (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, announces that its Board of Directors has accepted the resignation of Mr. Sylvain Chretien as President of the Company. In light of Mr. Chretien's resignation, the Board has decided not ... Read More...
Tetra Bio-Pharma Provides Update on PPP003 Inflammatory Cytokine Reduction Drug Program

Tetra Bio-Pharma Provides Update on PPP003 Inflammatory Cytokine Reduction Drug Program

OTTAWA, ON / ACCESSWIRE / May 11, 2020 / Tetra Bio-Pharma Inc. ("Tetra") (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that its Chief Operating Officer Steeve NĂ©ron participated in an interview on Saturday to discuss the Company's development of a drug program to treat certain symp... Read More...
Tetra Bio-Pharma Obtains Health Canada Approval for Renewal of its Veterinary Clinical Study

Tetra Bio-Pharma Obtains Health Canada Approval for Renewal of its Veterinary Clinical Study

No adverse events observed in study participantsHealth Canada VDD grants trial renewalOTTAWA, ON / ACCESSWIRE / May 11, 2020 / Tetra Bio-Pharma Inc. ("Tetra") (TBP.V)(TBPMF) , a leader in cannabinoid-derived drug discovery and development, is pleased to announce that its pilot clinical study to evaluate the tolerability and potential effi... Read More...
Tetra Bio-Pharma Discusses Development of PPP003 Drug for Cytokine Reduction with The Stock Day Podcast

Tetra Bio-Pharma Discusses Development of PPP003 Drug for Cytokine Reduction with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - May 7, 2020) - The Stock Day Podcast welcomed Tetra Bio-Pharma (OTCQB: TBPMF) ("the Company"), a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aimed at bringing novel prescription drugs and trea... Read More...
Tetra Bio-Pharma Provides PPP003 Inflammatory Cytokine Reduction Drug Program

Tetra Bio-Pharma Provides PPP003 Inflammatory Cytokine Reduction Drug Program

OTTAWA, ON / ACCESSWIRE / May 6, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V)(TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has now completed the modifications to the nonclinical safety program of PPP003 to ensure the launch of a Phase 1 trial in healthy volunteer... Read More...
Tetra Bio-Pharma Announces Drug Candidate as Potential Therapy for Managing Cytokine Release Syndrome

Tetra Bio-Pharma Announces Drug Candidate as Potential Therapy for Managing Cytokine Release Syndrome

Preclinical proof of concept of PPP003 as potential drug candidate for sepsis demonstratedTetra to develop PPP003 as potential drug therapy for the battle against COVID-19OTTAWA, ON / ACCESSWIRE / April 27, 2020 / Tetra Bio-Pharma Inc. ("Tetra") (TBP.V)(TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to... Read More...
Tetra Bio-Pharma Discusses FDA Orphan Drug Designation for Its Ophthalmic Program and Cannabinoid-Based Topical Cream with The Stock Day Podcast

Tetra Bio-Pharma Discusses FDA Orphan Drug Designation for Its Ophthalmic Program and Cannabinoid-Based Topical Cream with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - April 22, 2020) - The Stock Day Podcast welcomed Tetra Bio-Pharma (OTCQB: TBPMF) ("the Company"), a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aimed at bringing novel prescription drugs and t... Read More...
Tetra Expands on its Orphan Drug Development Program and Management Update

Tetra Expands on its Orphan Drug Development Program and Management Update

Tetra targeted ODD applications for ophthalmic, cancer and skin rare diseasesTetra receives its 5th Orphan Drug Designation (ODD)OTTAWA / ACCESSWIRE / April 22, 2020 / Tetra Bio-Pharma Inc. ("Tetra") (TBP.V)(TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce its Orphan Drug development strategy ... Read More...
Tetra Receives FDA Orphan Drug Designation for its Ophthalmic Clinical Program

Tetra Receives FDA Orphan Drug Designation for its Ophthalmic Clinical Program

Tetra's PPP003 cannabinoid drug receives Orphan Drug Designation for the Prevention of Proliferative VitreoretinopathyOTTAWA / ACCESSWIRE / April 15, 2020 / Tetra Bio-Pharma Inc. ("Tetra") (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has received U.S. Food and Drug Adminis... Read More...
Tetra BioPharma Confirms QIXLEEF Clinical Site Receives Renewal of DEA Schedule 1 License

Tetra BioPharma Confirms QIXLEEF Clinical Site Receives Renewal of DEA Schedule 1 License

DEA Renews Schedule 1 License for Scottsdale Research Institute (Plenitude clinical site)OTTAWA / ACCESSWIRE / April 14, 2020 / Tetra Bio-Pharma Inc. ("Tetra") (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that Dr. Sue Sisley's Scottsdale Research Institute received the renewal of ... Read More...
Tetra Offers Pro-Bono Regulatory and Quality Assurance Expertise to Companies Developing COVID-19 Solutions

Tetra Offers Pro-Bono Regulatory and Quality Assurance Expertise to Companies Developing COVID-19 Solutions

TETRA BIO-PHARMA VOLUNTEERS TO GUIDE MEDICAL DEVICE/ HEALTH-RELATED MANUFACTURERS OTTAWA, April 8, 2020 - Tetra Bio-Pharma Inc. ("Tetra") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development has joined the battle to fight the novel COVID-19 virus. The Company will mobilize its expertise in regulatory a... Read More...
Tetra Biopharma Confirms Type B Meeting Date With FDA Regarding HCC011

Tetra Biopharma Confirms Type B Meeting Date With FDA Regarding HCC011

OTTAWA, April 06, 2020 -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that the U.S. Food & Drug Administration ("FDA") has granted the Company’s request for a Type B meeting related to its proposed clinical program an... Read More...
Tetra Bio-Pharma Maps Out Cannabinoid Metabolites in Humans Following Inhalation of QIXLEEF

Tetra Bio-Pharma Maps Out Cannabinoid Metabolites in Humans Following Inhalation of QIXLEEF

Bioanalytical methods developed and validated for its clinical trials.Tetra initiates study to quantify phytocannabinoid metabolites and precursors and minor phytocannabinoids in human plasma.OTTAWA, April 02, 2020 -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and devel... Read More...
Coming Soon.

Delayed data (1h)
NameAgePositionAppointed
William M. Cheliak
Independent Chairman of the Board
--Independent Chairman of the Board2017
Guy Chamberland
Chief Executive Officer, Director, Chief Regulatory Officer
--Chief Executive Officer, Director, Chief Regulatory Officer2020
Jean-Francois Boily
Chief Financial Officer
--Chief Financial Officer2020
Graham Keith Wood
Chief Operating Officer
--Chief Operating Officer2020
Dania Scott
Senior Vice President - Commercial Strategy
--Senior Vice President - Commercial Strategy2020
Melanie Kelly
Chief Scientific Officer
--Chief Scientific Officer2019
Steve Neron
Chief Commercial Officer
--Chief Commercial Officer2020
Carl A. Merton
Independent Director
--Independent Director2017
Brent Norton
Independent Director
--Independent Director2020
Dale MacCandlish Weil
Independent Director
65Independent Director2020


Share this page